Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction

NCT03843515 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Oral Cavity Squamous Cell Carcinoma

Interventions

DRUG: Nivolumab

Sponsor

Amsterdam UMC, location VUmc

Collaborators

[object Object]